Pliant Therapeutics Inc (PLRX) posted a -0.72% change over the last five days signaling a new trend

On Tuesday, Pliant Therapeutics Inc (NASDAQ: PLRX) opened higher 1.48% from the last session, before settling in for the closing price of $1.35. Price fluctuations for PLRX have ranged from $1.10 to $16.10 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Healthcare Sector giant saw their annual sales slid by -52.88% over the last five years. Company’s average yearly earnings per share was noted 23.34% at the time writing. With a float of $54.10 million, this company’s outstanding shares have now reached $61.39 million.

The firm has a total of 171 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Pliant Therapeutics Inc (PLRX) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Pliant Therapeutics Inc is 11.86%, while institutional ownership is 85.31%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.

Pliant Therapeutics Inc (PLRX) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 23.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.07% during the next five years compared to -78.30% drop over the previous five years of trading.

Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators

Check out the current performance indicators for Pliant Therapeutics Inc (PLRX). In the past quarter, the stock posted a quick ratio of 11.03.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.61, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.22 in one year’s time.

Technical Analysis of Pliant Therapeutics Inc (PLRX)

Analysing the last 5-days average volume posted by the [Pliant Therapeutics Inc, PLRX], we can find that recorded value of 1.36 million was lower than the volume posted last year of 2.04 million. As of the previous 9 days, the stock’s Stochastic %D was 28.31%. Additionally, its Average True Range was 0.13.

During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 2.05%, which indicates a significant decrease from 25.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.26% in the past 14 days, which was lower than the 229.93% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.4643, while its 200-day Moving Average is $9.0113. Now, the first resistance to watch is $1.4233. This is followed by the second major resistance level at $1.4765. The third major resistance level sits at $1.5632. If the price goes on to break the first support level at $1.2834, it is likely to go to the next support level at $1.1967. Now, if the price goes above the second support level, the third support stands at $1.1435.

Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats

There are currently 61,386K shares outstanding in the company with a market cap of 84.10 million. Presently, the company’s annual sales total 0 K according to its annual income of -210,300 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -56,170 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.